Kintara Therapeutics (STU:3DMA) Receivables Turnover : 0.00 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kintara Therapeutics's Revenue for the three months ended in Jun. 2024 was €0.00 Mil. Kintara Therapeutics's average Accounts Receivable for the three months ended in Jun. 2024 was €0.00 Mil.

Kintara Therapeutics Receivables Turnover Historical Data

The historical data trend for Kintara Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Receivables Turnover Chart

Kintara Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Receivables Turnover

Get a 7-Day Free Trial

Kintara Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kintara Therapeutics's Receivables Turnover

For the Biotechnology subindustry, Kintara Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kintara Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Kintara Therapeutics's Receivables Turnover falls into.

Kintara Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Kintara Therapeutics's Receivables Turnover for the fiscal year that ended in Jun. 2024 is calculated as

	Receivables Turnover (A: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Jun. 2024 )	/ (	(Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Kintara Therapeutics's Receivables Turnover for the quarter that ended in Jun. 2024 is calculated as

	Receivables Turnover (Q: Jun. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Jun. 2024 )	/ (	(Accounts Receivable (Q: Mar. 2024 )	+	Accounts Receivable (Q: Jun. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Kintara Therapeutics (STU:3DMA) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Kintara Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

KTRA:USA 3DMA:Germany

Address

9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines